Volume 29, Number 12—December 2023
Research
Tecovirimat Resistance in Mpox Patients, United States, 2022–2023
Table 1
Category |
No. samples or isolates |
No. patients |
---|---|---|
Genomic testing | ||
Sequences analyzed | 3,247 | |
F13 substitutions other than E353K found (Table 2) |
130 |
76 |
Phenotype testing | ||
Submitted to CDC | 801 | 435 |
MPXV isolated | 164 | 83 |
Phenotype testing complete | 124 | 68 |
Tecovirimat resistant |
96 |
46 |
HIV-positive | 39 | |
CD4+ T-cell count <350 cell/µL | 31 | |
CD4+ T-cell count <200 cell/µL |
28 |
|
Deceased | 10 | |
Hospitalized | 34 | |
Tecovirimat treated | 39 |
*CDC, Centers for Disease Control and Prevention; MPXV, monkeypox virus.
Page created: October 18, 2023
Page updated: November 18, 2023
Page reviewed: November 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.